The increase in drug research being carried out by multinationals in China is creating growing demand for supporting contract services to international standards. Charles River Laboratories (CRL) first spotted what it considered to be this attractive opportunity several years ago, and decided to act on it.
"We started to see growing demands from clients for preclinical services in Asia around 2006 time, and decided to take a closer look," explained Chris Perkin, corporate senior vice-president and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?